Skip to main content

Advertisement

ADVERTISEMENT

Psychedelics Business

News
11/04/2021
Cybin, a biotechnology firm specializing in progressing psychedelic therapeutics, has announced the launch of the EMBARK psychedelic facilitator training program.
Cybin, a biotechnology firm specializing in progressing psychedelic therapeutics, has announced the launch of the EMBARK psychedelic facilitator training program.
Cybin, a biotechnology firm...
11/04/2021
Behavioral Healthcare Executive
News
10/28/2021
Mind Cure has signed a letter of intent to distribute Awakn Life Sciences’ ketamine-assisted therapy for alcohol use disorder in the US and Canada. MindMed has announced plans to expand its drug development pipeline. Revitalist, meanwhile, is...
Mind Cure has signed a letter of intent to distribute Awakn Life Sciences’ ketamine-assisted therapy for alcohol use disorder in the US and Canada. MindMed has announced plans to expand its drug development pipeline. Revitalist, meanwhile, is...
Mind Cure has signed a letter of...
10/28/2021
Behavioral Healthcare Executive
Scott Theaman, Beyond Marketing
Perspectives
10/26/2021
A ketamine clinic can provide an ideal alternative for individuals struggling with treatment-resistant depression. Here are a series of tips for developing a growth strategy to connect with more potential patients.
A ketamine clinic can provide an ideal alternative for individuals struggling with treatment-resistant depression. Here are a series of tips for developing a growth strategy to connect with more potential patients.
A ketamine clinic can provide an...
10/26/2021
Behavioral Healthcare Executive
News
10/21/2021
Numinus Wellness has finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived psilocybin extract, while an Awakn Life Sciences facility in the UK has received a key approval to begin offering...
Numinus Wellness has finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived psilocybin extract, while an Awakn Life Sciences facility in the UK has received a key approval to begin offering...
Numinus Wellness has finalized...
10/21/2021
Behavioral Healthcare Executive
News
10/13/2021
Novamind has launched a psychedelic palliative care program at its Murray, Utah, facility, and also obtained DEA licenses for conducting psilocybin research.
Novamind has launched a psychedelic palliative care program at its Murray, Utah, facility, and also obtained DEA licenses for conducting psilocybin research.
Novamind has launched a...
10/13/2021
Behavioral Healthcare Executive
News
10/01/2021
NeonMind announced it plans to establish a network of clinics that will provide psychedelic-based psychiatry treatments starting in 2022, while Delix Therapeutics has closed a $70 million Series A financing round to fund development of...
NeonMind announced it plans to establish a network of clinics that will provide psychedelic-based psychiatry treatments starting in 2022, while Delix Therapeutics has closed a $70 million Series A financing round to fund development of...
NeonMind announced it plans to...
10/01/2021
Behavioral Healthcare Executive
News
09/23/2021
Ketamine One has signed a letter of interest with Veterans Services USA to provide therapy at Blue Island Therapy Center in Illinois. Meanwhile, Awakn Life Sciences has acquired a facility in Norway.
Ketamine One has signed a letter of interest with Veterans Services USA to provide therapy at Blue Island Therapy Center in Illinois. Meanwhile, Awakn Life Sciences has acquired a facility in Norway.
Ketamine One has signed a letter...
09/23/2021
Behavioral Healthcare Executive
News
09/20/2021
Psychedelics wellness company Delic on Monday announced a deal to acquire Ketamine Wellness Centers, creating one of the largest psychedelic organizations in the United States.
Psychedelics wellness company Delic on Monday announced a deal to acquire Ketamine Wellness Centers, creating one of the largest psychedelic organizations in the United States.
Psychedelics wellness company...
09/20/2021
Behavioral Healthcare Executive
News
09/15/2021
Wesana Health Holdings is committing an initial $1.5 million to assessing the viability of the Multidisciplinary Association for Psychedelics Studies’ (MAPS) MDMA-assisted therapy for the treatment of traumatic brain injuries. Lennham...
Wesana Health Holdings is committing an initial $1.5 million to assessing the viability of the Multidisciplinary Association for Psychedelics Studies’ (MAPS) MDMA-assisted therapy for the treatment of traumatic brain injuries. Lennham...
Wesana Health Holdings is...
09/15/2021
Behavioral Healthcare Executive
News
09/10/2021
Biopharmaceutical firm Mydecine Innovations Group announced this week that it has partnered with Matthew Johnson, PhD, on a study to evaluate the use of Mydecine’s MYCO-001 compound as part of a smoking cessation program for individuals...
Biopharmaceutical firm Mydecine Innovations Group announced this week that it has partnered with Matthew Johnson, PhD, on a study to evaluate the use of Mydecine’s MYCO-001 compound as part of a smoking cessation program for individuals...
Biopharmaceutical firm Mydecine...
09/10/2021
Psych Congress Network

Advertisement

Advertisement

Advertisement